Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate a
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... The “Molecular Diagnostic Market by ... INAAT, DNA Sequencing), End User (Hospital, Laboratories), & ... Forecast to 2018” provides a detailed overview of ... trends, and strategies impacting the global molecular diagnostics ... the revenue and share analysis. , The global ...
(Date:10/27/2014)... 27, 2014 Called the NOAH ... eliminating several types of pediatric brain cancer. The ... in over 30 years of research and development. ... proves that one mom's determination can make a ... Halloween trick-or-treating, and it’s only fitting that we’ve ...
(Date:10/27/2014)... , Oct. 27, 2014 Pressure BioSciences, ... worldwide leader in the development and sale of ... sciences research market, today announced that Professor ... novel, accurate, highly reproducible, and robust method to ... high-throughput protein analysis on small needle biopsy samples ...
(Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
Breaking Biology Technology:Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... Berbee Information Networks Corp. has been recognized ... provide project management services. , ,The Madison-based IT solutions ... headquartered in the Midwest to achieve Microsoft's Enterprise Project ... recognition of Berbee's expertise in serving businesses that require ...
... Madison - A young company with a preventive solution ... the 2006 G. Steven Burrill Technology Business Plan Competition, but ... to home, they better act quickly. , , Din ... winning business plan. Khaja M. Din, president IPIC ...
... Wisconsin Technology Council , a policy advisor to the ... announced eight additions to its board of directors. , ... a board that includes more than three dozen members ... technology organization leaders: , , Eric Apfelbach, president and ...
Cached Biology Technology:Winner of Burrill competition courted by North Carolina investors 2Winner of Burrill competition courted by North Carolina investors 3
(Date:10/30/2014)... researchers have developed a suite of technologies that can ... which has applications in everything from search and rescue ... developed a platform for computer-mediated communication between humans and ... interpreting dogs, behavioral signals and sending them clear and ... assistant professor of computer science at NC State and ...
(Date:10/29/2014)... Cancer suffers who lose their hair as a consequence ... that will improve the scalp cooling technology that prevents ... and is being pioneered by global scalp cooling manufacturing ... with the biology department of the University of Huddersfield. ... Omar Hussain, who has a background in the pharmacology ...
(Date:10/29/2014)... have been blamed for increasing the risk of ... family history of schizophrenia, are widely accepted. Others, ... a parasite transmitted by soil, undercooked meat and ... A new study by Gary Smith, professor of ... Pennsylvania,s School of Veterinary Medicine, used epidemiological modeling ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... producing proteins that moonlight, having different roles at different ... killed. The moonlighting activity of one enzyme from the ... of broad-spectrum antibiotics, according to a paper published in ... "Glutamate racemase, or MurI, is an enzyme ...
... many recent reports documenting the therapeutic efficacy of short ... may actually be describing non-specific therapeutic effects related to ... according to a paper in the September 2008 issue ... , a peer-reviewed journal published by Mary Ann Liebert, ...
... NY, Sept. 2, 2008) People concerned about the ... families and communities will have a unique opportunity to ... about the causes, symptoms and progression of such illnesses ... learn about current and potential treatments. In an ...
Cached Biology News:Energy-saving bacteria resist antibiotics 2Previous claims of siRNA therapeutic effects called into question by report in human gene therapy 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 3
Vitellogenin (Japanese medaka) Standard...
nuclear RNA export factor 1, mRNA...
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
Biology Products: